These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29229829)

  • 1. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
    Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.
    Langut Y; Edinger N; Flashner-Abramson E; Melamed-Book N; Lebendiker M; Levi-Kalisman Y; Klein S; Levitzki A
    Oncotarget; 2017 Apr; 8(15):24046-24062. PubMed ID: 28445962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
    Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
    Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
    Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
    Kularatne SA; Wang K; Santhapuram HK; Low PS
    Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
    Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
    Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
    Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
    Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
    Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
    Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.
    Shir A; Ogris M; Roedl W; Wagner E; Levitzki A
    Clin Cancer Res; 2011 Mar; 17(5):1033-43. PubMed ID: 21196415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Silencing effect of cell-specific RNA interference plasmid pPSMAe/p-shNS-ploy(A) loaded by transgenic vector Tf-PEG-PEI targeting nucleostemin on prostate cancer cells in vitro].
    Liu RL; Wang WY; Zhang ZH; Xu Y
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):725-9. PubMed ID: 23291063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.